While in other FGFR-altered tumors, including cholangiocarcinomas [140] and bladder cancers [141], specific FGFR inhibitors yielded impressive response, in CRC data on FGFR1 and FGFR2 amplifications as novel targets are limited. Here, FGFR1 is linked to colorectal carcinoma.